Document is current
Any future updates will be listed below
-
Authors
Fidelio, Giacomo
Ruggieri, Maria Pia
Crisanti, Luca
Valli, Gabriele
De Marco, Francesca
Bergman, Andreas
Santos, Karine
Hartman, Oliver
Di Somma, Salvatore
,
- License Information
-
More Information
Article History
Received: 14 July 2025
Accepted: 18 July 2025
First Online: 24 July 2025
Declarations
:
: The study protocol was approved by our local ethics committee (Lazio 1 Ethical Committee, protocol number 0945/2024) and conducted in agreement with the Declaration of Helsinki and its successive amendments. Before enrolment, informed consent was obtained from each patient (or their legal representatives).
: Not Applicable.
: Oliver Hartmann, Karine Santos and Andreas Bergmann are employees of 4TEEN4 Pharmaceuticals GmbH. 4TEEN4 Pharmaceuticals GmbH holds patents related to the DPP3 biomarker and the anti-DPP3 therapy (procizumab).
